title: Pharmaceuticals and Medical Devices: Cost Savings.
authors.forename: David J
authors.initials: DJ
authors.lastname: Steiner
mesh_terms: D000927:Anticonvulsants / Q000191:economics / Q000627:therapeutic use; D001688:Biological Products / Q000191:economics; D059451:Biosimilar Pharmaceuticals / Q000191:economics; D002170:Canada; D014487:Centers for Medicare and Medicaid Services, U.S. / Q000191:economics / Q000331:legislation & jurisprudence; D002908:Chronic Disease; D003132:Commerce; D017046:Cost Savings; D003669:Deductibles and Coinsurance; D017277:Drug Approval / Q000191:economics / Q000331:legislation & jurisprudence; D016527:Drug Costs / Q000331:legislation & jurisprudence* / Q000639:trends; D016568:Drugs, Generic / Q000191:economics*; D017850:Economics, Pharmaceutical / Q000331:legislation & jurisprudence*; D004837:Epinephrine / Q000191:economics; D005375:Financial Audit; D006801:Humans; D000068877:Imatinib Mesylate / Q000191:economics; D007342:Insurance Benefits / Q000191:economics / Q000331:legislation & jurisprudence; D019458:Insurance Coverage / Q000191:economics / Q000331:legislation & jurisprudence; D007356:Insurance, Pharmaceutical Services / Q000191:economics* / Q000331:legislation & jurisprudence; D007880:Legislation, Drug / Q000191:economics*; D055118:Medication Adherence; D054539:Medication Therapy Management / Q000191:economics; D009270:Naloxone / Q000191:economics; D010594:Pharmacies / Q000191:economics / Q000331:legislation & jurisprudence; D013219:State Government; D013810:Therapeutic Equivalency; D014481:United States; D014486:United States Food and Drug Administration / Q000191:economics / Q000331:legislation & jurisprudence
chemical_list: D000927:Anticonvulsants; D001688:Biological Products; D059451:Biosimilar Pharmaceuticals; D016568:Drugs, Generic; D009270:Naloxone; D000068877:Imatinib Mesylate; D004837:Epinephrine